Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 11, 2026Blood AdvancesOpen Access

Prognostic factors and survival outcomes in relapsed/refractory aggressive B-cell lymphomas treated with epcoritamab

View Full Paper
Ask AI
Bookmark
Share

Authors

ABAllison M. BockLFLei FengACAmrita Chauhan

Discussion

Loading...

Member takes

Overview

Randomized trial finds survival outcomes in relapsed/refractory aggressive B-cell lymphomas, suggesting cautious optimism for future treatment.

Key Points

  • To evaluate prognostic factors and survival outcomes in patients with relapsed/refractory aggressive B-cell lymphomas treated with epcoritamab.
  • Analyzed 157 adult patients with R/R aggressive B cells treated with epcoritamab in real-world settings between 2023-2025.
  • Data collected included response rates, progression free survival, and overall survival metrics.
  • Study conducted at 9 centers in the Collaborative US Bispecifics Consortium (CUBIC).
  • Best overall response rate (ORR) was 49.6% and best complete response rate (CRR) was 31.9%.
  • 1-year progression free survival (PFS) was 29% (95% CI: 22-37%) and overall survival (OS) was 38% (95% CI: 31-47%).
  • Inferior outcomes were linked to high IPI scores, elevated LDH levels, and patients with refractory disease.

Cite This Study

Bock et al. (2026) studied this question.

synapsesocial.com/papers/6a2a50e080c8f91e7f39d4d9https://doi.org/10.1182/bloodadvances.2026020171
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy and safety of epcoritamab in relapsed or refractory large B-cell lymphoma: 3-year update from the EPCORE NHL-1 trial2026 · 4 citations
  2. 2Evaluation of prognostic factors and survival outcomes in patients with Relapsed/Refractory (R/R) large B-cell lymphomas (LBCLs) treated with epcoritamab2025
  3. 3Clinical Outcomes and Exploratory Longitudinal CTL/Vβ Repertoire Remodeling in Patients with Relapsed or Refractory Large B-Cell Lymphoma and Follicular Lymphoma Treated with Epcoritamab2026 · 1 citations
  4. 4Sustained remissions beyond 4 years with epcoritamab monotherapy: Long term follow-up results from the pivotal EPCORE NHL-1 trial in patients with relapsed or refractory large B-cell lymphoma2025
  5. 5Epcoritamab plus rituximab, dexamethasone, cytarabine, oxaliplatin/carboplatin induces deep and durable responses in transplant-eligible patients with relapsed or refractory diffuse large B-cell lymphoma: results from the EPCORE NHL-2 trial2026